Future Fund LLC Grows Stake in Gilead Sciences, Inc. $GILD

Future Fund LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,578 shares of the biopharmaceutical company’s stock after buying an additional 1,063 shares during the period. Future Fund LLC’s holdings in Gilead Sciences were worth $729,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Midwest Trust Co purchased a new position in Gilead Sciences during the 2nd quarter valued at $994,000. DJE Kapital AG lifted its position in shares of Gilead Sciences by 121.7% in the 2nd quarter. DJE Kapital AG now owns 140,881 shares of the biopharmaceutical company’s stock worth $15,461,000 after purchasing an additional 77,335 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Gilead Sciences by 94.2% during the 2nd quarter. Acadian Asset Management LLC now owns 767,854 shares of the biopharmaceutical company’s stock valued at $85,121,000 after purchasing an additional 372,374 shares in the last quarter. Sound View Wealth Advisors Group LLC increased its position in shares of Gilead Sciences by 167.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 27,134 shares of the biopharmaceutical company’s stock valued at $3,008,000 after buying an additional 17,007 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Gilead Sciences by 7.4% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,481,650 shares of the biopharmaceutical company’s stock worth $275,141,000 after buying an additional 171,765 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 3.7%

Shares of NASDAQ GILD opened at $118.84 on Monday. The firm’s 50 day moving average price is $116.49 and its 200-day moving average price is $112.26. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.61. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market cap of $147.46 billion, a PE ratio of 23.67, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares in the company, valued at $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 71,500 shares of company stock valued at $8,336,040 over the last ninety days. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Citigroup raised their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Truist Financial reissued a “buy” rating and set a $145.00 price objective (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, TD Cowen increased their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $127.82.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.